Toxicities Following CAR-T Therapy for Hematological Malignancies
Cette étude passe en revue les données évaluant les toxicités des immunothérapies à base de lymphocytes CAR-T chez des patients atteints d'un cancer hématologique réfractaire ou récidivant et présente les stratégies pour prévenir et prendre en charge ces toxicités
Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in patientswith relapsed/refractory hematological malignancies. Research is also extending toother diseases, including solid tumors, infections and autoimmune disorders. As livingdrugs, CAR-T cells are associated with potentially life-threatening immunologicaltoxicities, which frequently require a multidisciplinary team approach. Cytokine-releasesyndrome, immune effector cell-associated neurotoxicity syndrome, infections and hematotoxicity(including cytopenias, immune reconstitution dysfunction and hypogammaglobulinemia)are associated with significant morbidity and mortality. This review takes a practica lapproach to summarize current knowledge on CAR-T toxicity, addressing pathogeny, riskfactors, and prophylactic and therapeutic strategies.